NCT06209892View on ClinicalTrials.gov

Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular Thrombosis

NANot yet recruitingINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Embolism and ThrombosisAnticoagulation

Interventions

PROCEDURE

Extended anticoagulation

This study plan will extend the duration of rivaroxaban 20mg in the experimental group to 12 months. The regular anticoagulation group will take the drug for 6 months

All Listed Sponsors

lead

Chinese Academy of Medical Sciences, Fuwai Hospital

OTHER

NCT06209892 - Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular Thrombosis | Biotech Hunter | Biotech Hunter